stockrowIonis Pharmaceuticals, Inc.
IONS Healthcare Biotechnology
Ionis Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $943.7 million, up 33.8% from fiscal 2024.
- Revenue
- −40.7%
- EPS
- −188.5%
- Free cash flow
- +299.3%
- Total debt
- +116.0%
Quarter to June 2026, against a year earlier
Follow IONS
Alert me
Ionis Pharmaceuticals, Inc. (IONS) Shares outstanding
Ionis Pharmaceuticals, Inc.'s shares outstanding at the end of fiscal 2025 was $160.0M, up 7.02% from $149.5M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $165.4M. Over the past ten years it has ranged from $119.7M (fiscal 2015) to $160.0M (fiscal 2025) — the current reading is the highest in ten years. Ionis Pharmaceuticals, Inc. ranks 67th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $160.0M | 7.02% |
| FY2024 | $149.5M | 4.42% |
| FY2023 | $143.2M | 0.95% |
| FY2022 | $141.8M | 0.59% |
| FY2021 | $141.0M | 1.01% |
| FY2020 | $139.6M | (8.85%) |
| FY2019 | $153.2M | 14.25% |
| FY2018 | $134.1M | 6.31% |
| FY2017 | $126.1M | 4.27% |
| FY2016 | $120.9M | 1.01% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $165.4M | 0.33% |
| Mar 2026 | $164.9M | 3.04% |
| Dec 2025 | $160.0M | 0.15% |
| Sep 2025 | $159.8M | (12.38%) |
| 42 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| IMVT Immunovant, Inc. compare | $205.5M |
| IONS Ionis Pharmaceuticals, Inc. | $165.4M |
| CGON CG Oncology, Inc. compare | $88.2M |
| MIRM Mirum Pharmaceuticals, Inc. compare | $66.1M |
| ORKA Oruka Therapeutics, Inc. compare | $62.9M |
| KOD Kodiak Sciences Inc. compare | $62.6M |
| AXSM Axsome Therapeutics, Inc. compare | $52.4M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | $40.2M |
| LGND Ligand Pharmaceuticals Incorporated compare | $20.0M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on IONS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement